Skip to main content

Table 4 Prognostic factors in the COX proportional Hazards Model

From: Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer

Variables

Risk ratio

Univariate 95%CI

P value

Risk ratio

Multivariate 95%CI

P value

Age (years)

      

 ≤ 53/ > 53

1.768

(0.981–3.187)

0.058

   

FIGO stage

      

III/IV

1.518

(0.838–2.751)

0.168

   

PS

      

0/1

0.832

(0.450–1.537)

0.557

   

NAC cycles

      

1,2/3,4

1.522

(0.799–2.900)

0.202

   

CA-125 value (U/mL)

      

 ≤ 670/ > 670

0.748

(0.406–1.380)

0.354

   

 ≤ 100/ > 100

0.770

(0.182–3.258)

0.722

   

Residual disease

      

R0/R1

0.207

(0.073–0.588)

0.003

0.180

(0.064–0.509)

0.001

BMI

      

 ≤ 23/ > 23

1.518

(0.838–2.751)

0.168

   

CA-125 drop rate

      

 ≥ 90%/ < 90%

0.743

(0.408–1.354)

0.332

   

 ≥ 95%/ < 95%

0.565

(0.261–1.222)

0.147

   

 ≤ 100/ > 100U/mL

0.728

(0.405–1.309)

0.289

   

NAC regimens

      

Nab-TC/TC

0.492

(0.271–0.894)

0.02

0.411

(0.224–0.753)

0.004

  1. FIGO: international federation of obstetrics and gynecology, PS: performance status, NAC: neoadjuvant chemotherapy, IDS: intermittent debulking surgery, CA-125: carbohydrate Antigen 125, BMI: body mass index, R1: diameter of residual lesion < 1 cm, R0: no macroscopic residual tumor